MPM BioVentures 2014 and Affiliates Reduce Stake in Werewolf Therapeutics via Open Market Sales

On May 12, 2026, MPM BioVentures 2014, L.P. and a group of affiliated entities filed an Amendment No. 7 to their Schedule 13D for Werewolf Therapeutics, Inc. (HOWL). The filing reports a series of open market sales of common stock conducted between May 6, 2026, and May 12, 2026. During this period, the reporting persons sold shares at prices ranging from approximately $0.62 to $0.77 per share. Following these transactions, MPM BioVentures 2014, L.P. directly holds 792,254 shares, representing a 1.6% ownership stake based on 48,596,817 shares outstanding as of May 1, 2026. The broader reporting group, which includes Ansbert Gadicke, Luke Evnin, and Todd Foley, maintains various levels of indirect beneficial ownership through entities such as MPM BioVentures 2014 GP LLC and UBS Oncology Impact Fund L.P. The sales were executed to reduce the group's overall position in the issuer. Total aggregate ownership reported for the most significant individual filer, Ansbert Gadicke, stands at 1,826,646 shares or 3.8%.